DelveInsight’s report, “Asthma Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Asthma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.
Additionally, it examines Asthma market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.
Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/asthma-market
Some of the key facts of the Asthma Market Report:
-
The asthma market size across the 7MM was valued at approximately USD 27 billion in 2024 and is expected to grow at a CAGR of 1.9%, with continued expansion anticipated throughout the forecast period from 2025 to 2034.
-
In March 2026, After discontinuing its branded versions of the asthma inhaler Flovent in early 2024, GSK continued supplying “authorized generics,” which are identical products marketed under different labels by partner companies. Now, genuine competition has emerged following the U.S. Food and Drug Administration approval of Glenmark Pharmaceuticals’s fluticasone propionate inhalation aerosol. This inhaled corticosteroid works by reducing lung inflammation and is indicated as a maintenance therapy for patients aged 4 years and older to help prevent symptoms such as wheezing and shortness of breath. As the first company to secure FDA approval for a generic version of Flovent, Glenmark is granted 180 days of market exclusivity before additional generic competitors can enter. The company plans to begin distribution of the product in March.
-
In March 2026, The U.S. Food and Drug Administration has approved the first generic version of Flovent HFA, which delivers 44 micrograms per actuation, for the maintenance treatment of asthma in patients aged 4 years and older. Flovent HFA is an inhaled corticosteroid that works by reducing lung inflammation, helping to prevent symptoms such as wheezing and shortness of breath.
-
In February 2026, The U.S. Food and Drug Administration has approved GSK’s Exdensur for the treatment of severe asthma in patients aged 12 years and older. The approval is based on findings from the SWIFT clinical trials, which showed a significant reduction in asthma exacerbations. As the first ultra-long-acting biologic with a six-month dosing interval, depemokimab represents a major advancement in asthma care, shifting from monthly or bi-monthly injections to a convenient twice-yearly regimen.
-
In December 2025, GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved Exdensur as an add-on maintenance therapy for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype. Exdensur is the first ultra-long-acting biologic being developed for respiratory diseases driven by type 2 inflammation, including severe asthma, and is engineered with an extended half-life to enable twice-yearly dosing. The approval is based on data from the Phase III SWIFT-1 and SWIFT-2 trials, where depemokimab demonstrated a sustained reduction in exacerbations with only two doses per year compared to placebo, in addition to standard care.
-
In September 2025, Areteia Therapeutics reported positive Phase III results from the EXHALE-4 trial, evaluating dexpramipexole as an oral add-on therapy for eosinophilic asthma, demonstrating its potential to improve outcomes in patients with this severe form of the disease.
-
In September 2025, The U.S. FDA approved a supplemental new drug application for Airsupra (albuterol/budesonide), updating its U.S. prescribing information to include new data for patients with mild asthma. According to AstraZeneca, this approval broadens Airsupra’s use as an anti-inflammatory rescue therapy for adults across all levels of asthma severity.
-
In July 2025, Asthma severity is driven by multiple inflammatory pathways, making a universal treatment approach challenging. As a result, researchers are investigating precision medicine for asthma, which focuses on identifying disease subtypes using specific biological markers (biomarkers) and customizing therapies accordingly. “Through a trial that applies precision medicine to match patients with treatments best suited to their individual profiles, we aim to replicate a strategy that has proven effective in cancer research. This platform trial design allows the simultaneous evaluation of multiple interventions in enrolled participants,” researchers explained.
-
In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), achieved the primary endpoints in two Phase III asthma trials. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies showed that Breztri significantly and clinically improved lung function compared to dual-combination ICS/LABA treatments. Both randomized, double-blind trials enrolled 4,434 patients with uncontrolled asthma to assess Breztri’s efficacy as a potential therapeutic option.
-
In February 2025, Enveda, a biotechnology firm utilizing AI to convert natural compounds into novel therapies, has announced the expansion of its lead asset, ENV-294, into a new indication: asthma. Initially developed for atopic dermatitis, this innovative treatment presents a promising approach for managing respiratory inflammatory conditions. To advance this initiative, Enveda has formed an advisory board comprising leading experts in asthma research and clinical care.
-
In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD.
-
Projections indicate that depemokimab could reach around USD 1.7 billion in revenue across the 7MM by 2034.
-
The asthma market in the United States was valued at approximately USD 21.5 billion in 2024 and is projected to expand at a CAGR of 2.1% over the forecast period, supported by increased disease awareness and the availability of new therapeutic options.
-
In the same year, the combined asthma market across the EU4 and the UK reached about USD 4.5 billion, making up nearly 17% of the total market revenue in the 7MM. DelveInsight estimates that the UK held the largest share within this region, contributing around USD 1.7 billion in 2024, while Spain accounted for the smallest share at roughly USD 460 million.
-
Japan’s asthma market was valued at approximately USD 910 million in 2024 and is expected to rise at a CAGR of 1.4% through 2025–2034.
-
According to DelveInsight, the 7MM recorded roughly 57 million diagnosed prevalent cases of asthma in 2024, and this figure is expected to grow by 2034. The United States accounted for nearly 26 million of these cases, including about 21 million adults, with the prevalence anticipated to rise throughout 2025–2034. In 2024, asthma affected approximately 15.2 million females in the US, significantly higher than the 10.6 million cases reported among males.
-
In 2024, asthma cases in the US by severity included approximately 9.3 million individuals with intermittent asthma, about 7.4 million with mild disease, close to 7.1 million with moderate asthma, and around 1.9 million with severe asthma.
-
Across the EU4 and the UK, the United Kingdom reported the highest number of diagnosed prevalent cases, reaching roughly 8.4 million, while Spain had the lowest at about 2.6 million. In France, adult asthma cases were substantially higher, with nearly 3.4 million adults affected compared to around 1.3 million pediatric cases.
-
In Japan, severe asthma driven by Type 2 inflammation accounted for an estimated 248,000 cases in 2024, versus approximately 55,000 Non–Type 2 cases.
-
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
-
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
-
The Asthma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.
Asthma Overview
Asthma is a chronic inflammatory disease of the airways that makes breathing difficult. It causes the air passages in the lungs to become swollen and narrowed, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Triggers may include allergens, pollution, exercise, respiratory infections, cold air, and stress. Asthma symptoms can vary from mild to severe and may occur occasionally or persistently. Although there is no cure, asthma can be effectively managed with medications (such as inhalers), avoidance of triggers, and regular monitoring, enabling most patients to lead normal, active lives.
To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast
Asthma Epidemiology
The Asthma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Asthma Epidemiology Segmentation:
The Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Diagnosed Prevalent Cases of Asthma in the 7MM
-
Age-specific Cases of Asthma in the 7MM
-
Gender-specific Cases of Asthma in the 7MM
-
Severity-specific Cases of Asthma in the 7MM
-
Type-specific Severe Cases of Asthma in the 7MM
Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast
Asthma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Asthma Therapies and Key Companies
-
DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
-
TEZSPIRE (tezepelumab): Amgen/AstraZeneca
-
FASENRA (benralizumab): AstraZeneca
-
Dexpramipexole: Areteia Therapeutics
-
Depemokimab (GSK3511294): GlaxoSmithKline
-
BREZTRI AEROSPHERE (BGF; PT-010): AstraZeneca
-
GSK3511294 (Depemokimab): GlaxoSmithKline
-
Masitinib (AB07105): AB Science
-
PT010: AstraZeneca
-
Dexpramipexole Dihydrochloride: Areteia Therapeutics
-
ARS 1: ARS Pharmaceuticals, Inc.
-
MEDI3506 (tozorakimab): AstraZeneca
-
AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
-
Atuliflapon (AZD5718): AstraZeneca
-
Amlitelimab: Sanofi
-
Rilzabrutinib: Sanofi
-
BOXABAN (Ifetroban): Cumberland Pharmaceuticals
-
RG6341 (GDC-6599): Genentech Research/Roche
-
CBP-201: Suzhou Connect Biopharmaceuticals
-
AVTX-002 (Quisovalimab): Avalo Therapeutics
-
MRx-4DP0004: 4D Pharma plc
-
SB010: Sterna Biologicals
Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape
Asthma Market Drivers
-
Rising prevalence of asthma worldwide, especially in children and urban populations.
-
Increasing air pollution and environmental triggers, contributing to higher disease incidence.
-
Advancements in asthma therapies, including biologics, inhalers, and combination treatments.
-
Growing awareness and early diagnosis through improved healthcare access and education.
-
Supportive government initiatives and healthcare programs promoting asthma management and patient care.
Asthma Market Barriers
-
High cost of advanced therapies and biologics, limiting patient accessibility.
-
Poor patient adherence to long-term treatment regimens, reducing treatment effectiveness.
-
Variability in asthma severity and phenotypes, complicating personalized treatment strategies.
-
Limited access to healthcare in low- and middle-income regions, affecting diagnosis and management.
-
Potential side effects of chronic medication use, such as corticosteroids, which may deter long-term therapy.
Scope of the Asthma Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
-
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
-
Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
-
Asthma Market Dynamics: Asthma market drivers and Asthma market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement
To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Asthma Market Report Introduction
2. Executive Summary for Asthma
3. SWOT analysis of Asthma
4. Asthma Patient Share (%) Overview at a Glance
5. Asthma Market Overview at a Glance
6. Asthma Disease Background and Overview
7. Asthma Epidemiology and Patient Population
8. Country-Specific Patient Population of Asthma
9. Asthma Current Treatment and Medical Practices
10. Asthma Unmet Needs
11. Asthma Emerging Therapies
12. Asthma Market Outlook
13. Country-Wise Asthma Market Analysis (2020–2034)
14. Asthma Market Access and Reimbursement of Therapies
15. Asthma Market Drivers
16. Asthma Market Barriers
17. Asthma Appendix
18. Asthma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
